當前，全球疫情形勢仍然十分嚴峻，新冠疫苗的好消息接連傳出，給飽受疫情煎熬的人們帶來曙光。
不僅疫苗的研發在緊鑼密鼓地進行，各國疫苗審批進程也在紛紛加速。繼輝瑞疫苗在英國通過審批、加拿大和美國相繼批准投入緊急使用之後，歐洲其他國家也正在加緊審批輝瑞和另一款疫苗。
中國國藥集團研發生產的新冠疫苗也獲得埃及、墨西哥、印尼等國的青睞，並已在阿聯酋正式註冊。
More countries are giving the go-ahead to the emergency use of coronavirus vaccines as the first shipments of the antidote reach their buyers.
Following the UK okaying the use of the Pfizer vaccine, Canada and the United States followed suit while across Europe, governments are accelerating the approval of different vaccines.
Last week, Egypt also received its first shipment of vaccines developed by China National Pharmaceutical Group (Sinopharm) and will get more deliveries soon. Mexico signed an agreement to buy 35 million doses of Chinese firm CanSino Biologics' COVID-19 vaccine, while the UAE “officially registered” the vaccine developed by Sinopharm, which it found was 86 percent efficient, citing an interim analysis of late-stage clinical trials.
為保證本國疫苗供應充足，西方發達國家爭相搶購疫苗，英美等國更“先下手為強”，直接與疫苗製造商簽訂預購合同。以加拿大為例，作為目前購買疫苗最多的國家，該國已訂購足夠保護每個加拿大人接種五次的疫苗量。預計到2021年底，西方發達國家所囤積的疫苗數量將達到本國人口的近三倍。
根據杜克大學全球健康創新中心的數據，早在疫苗問世以前，中高收入國家已經搶先預購了近90億劑的疫苗。中等收入國家也正在加大疫苗購買劑量，巴西和印度已經獲得的疫苗劑量基本可以覆蓋大約一半的人口。
An analysis from researchers at Duke University’s Global Health Innovation Center found that middle- and high-income countries have already purchased and pre-ordered nearly nine billion vaccine doses before any pharmaceutical product was available on the market.
Middle-income countries are also reserving their share of the doses. Brazil and India already have secured the right to enough vaccines to cover about half of their population, the analysis noted.
“人民疫苗聯盟”最新研究報告數據顯示，一些富裕國家不惜用高價“攔截”了各大生物製藥公司所生產的約53%的疫苗。
與此同時，欠發達國家和地區正深陷疫苗難求的窘境。
報告指出，目前莫德納公司新冠疫苗的所有份額和輝瑞公司超過96%的疫苗都已經被財力雄厚的發達國家掃購一空。如果放任哄搶疫苗的行為繼續下去，
至少有67個貧窮國家明年只能為其十分之一的人口接種新冠疫苗，將有數十億人被剝奪接種疫苗的機會。自疫苗競賽開始以來， 為避免“疫苗民族主義”加劇，各國都在呼籲採取合作方式進行疫苗開發和分配。多個國際組織和專家都對西方發達國家買斷世界上絕大多數疫苗供應的做法表示了擔憂，一旦最早幾批疫苗被富裕國家瓜分殆盡，貧窮國家將無法得到保障。
Since the arms race for a coronavirus vaccine, there have been calls for cooperation in vaccine development and distribution in order to avoid the intensification of "vaccine nationalism."
Global organizations and experts have shown concern about the practice of developed countries to buy out the vast majority of vaccine supplies around the world. Once the first batch of vaccines is sold out by rich countries, there is no guarantee that poor countries could get their share.
為此，世界衛生組織多次呼籲各國政府將預防新冠病毒的疫苗變成“公共產品”，使所有國家的高危群體都能優先接種，世界衛生組織總幹事譚德塞敦促更多國家加入“新冠肺炎疫苗實施計劃”（COVAX），以確保疫苗的公平分配。
目前，包括中國在內，已有189個國家和經濟體加入該行列，其中有92個為中低收入國家。COVAX計劃到2021年底向全球提供20億劑疫苗，但這仍只能滿足參與該計劃的國家20%左右的需求。
The Director-General of the World Health Organization (WHO) Tedros Adhanom Ghebreyesus has said the only way to recover from the pandemic was by working together and making sure poorer countries had fair access to a vaccine. China announced it is joining the COVAX initiative on October 9 to help the world fight against the pandemic. The talks are on with the WHO to have its domestically manufactured vaccines assessed for international use.
對於絕大多數欠發達國家而言，儘管每日都有數以萬計的人因新冠病毒死亡，但等待仍是唯一選擇。
當新冠疫情成為一場席捲全球的公共衛生安全危機，任何國家都無法置身事外。西方國家大量囤積疫苗的行為不僅在全球範圍內破壞了確保所有人都不受新冠病毒侵害的努力，更不利於新冠疫情及早結束。
“在所有人都安全之前，沒有人是安全的”。
